160 related articles for article (PubMed ID: 34299462)
1. Discovery of Novel 2,4-Dianilinopyrimidine Derivatives Containing 4-(Morpholinomethyl)phenyl and
Han C; Shen K; Wang S; Wang Z; Su F; Wu X; Hu X; Li M; Han J; Wu L
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299462
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity.
Duan YT; Yao YF; Huang W; Makawana JA; Teraiya SB; Thumar NJ; Tang DJ; Tao XX; Wang ZC; Jiang AQ; Zhu HL
Bioorg Med Chem; 2014 Jun; 22(11):2947-54. PubMed ID: 24792811
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity.
Dao P; Lietha D; Etheve-Quelquejeu M; Garbay C; Chen H
Bioorg Med Chem Lett; 2017 Apr; 27(8):1727-1730. PubMed ID: 28284808
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors.
Li R; Gong L; Sun J; Liang Z; He J; Huang J; Ning X; Song H; Li R; Zhang Q; Lin Z; Yin Y
Bioorg Chem; 2024 Mar; 144():107134. PubMed ID: 38237389
[TBL] [Abstract][Full Text] [Related]
8. Novel benzotriazole N-acylarylhydrazone hybrids: Design, synthesis, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and FAK inhibition.
Kassab AE; Hassan RA
Bioorg Chem; 2018 Oct; 80():531-544. PubMed ID: 30014921
[TBL] [Abstract][Full Text] [Related]
9. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
Mustafa M; Abd El-Hafeez AA; Abdelhamid D; Katkar GD; Mostafa YA; Ghosh P; Hayallah AM; Abuo-Rahma GEA
Eur J Med Chem; 2021 Oct; 222():113569. PubMed ID: 34111829
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
Chen T; Liu Y; Shi M; Tang M; Si W; Yuan X; Wen Y; Chen L
Bioorg Med Chem Lett; 2021 Dec; 54():128433. PubMed ID: 34757216
[TBL] [Abstract][Full Text] [Related]
11. Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells.
Wang L; Ai M; Yu J; Jin L; Wang C; Liu Z; Shu X; Tang Z; Liu K; Luo H; Guan W; Sun X; Ma X
Eur J Med Chem; 2019 Jun; 172():154-162. PubMed ID: 30978560
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation, and molecular docking studies of novel 1,3,4-oxadiazole derivatives possessing benzotriazole moiety as FAK inhibitors with anticancer activity.
Zhang S; Luo Y; He LQ; Liu ZJ; Jiang AQ; Yang YH; Zhu HL
Bioorg Med Chem; 2013 Jul; 21(13):3723-9. PubMed ID: 23673215
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
Su Y; Li R; Ning X; Lin Z; Zhao X; Zhou J; Liu J; Jin Y; Yin Y
Eur J Med Chem; 2019 Sep; 177():32-46. PubMed ID: 31129452
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors.
Xie H; Lin X; Zhang Y; Tan F; Chi B; Peng Z; Dong W; An D
Bioorg Med Chem Lett; 2020 Nov; 30(21):127459. PubMed ID: 32784087
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
Dao P; Smith N; Tomkiewicz-Raulet C; Yen-Pon E; Camacho-Artacho M; Lietha D; Herbeuval JP; Coumoul X; Garbay C; Chen H
J Med Chem; 2015 Jan; 58(1):237-51. PubMed ID: 25180654
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
Wang S; Zhang RH; Zhang H; Wang YC; Yang D; Zhao YL; Yan GY; Xu GB; Guan HY; Zhou YH; Cui DB; Liu T; Li YJ; Liao SG; Zhou M
Eur J Med Chem; 2021 Oct; 222():113573. PubMed ID: 34091209
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel FAK inhibitors with better selectivity over IR than TAE226.
Chen T; Liu Y; Liu J; Tang M; Huang H; Bai C; Si W; Yang T; Yuan X; Wen Y; Chen L
Bioorg Chem; 2022 Jul; 124():105790. PubMed ID: 35452915
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity.
Qu M; Liu Z; Zhao D; Wang C; Zhang J; Tang Z; Liu K; Shu X; Yuan H; Ma X
Bioorg Med Chem; 2017 Aug; 25(15):3989-3996. PubMed ID: 28576633
[TBL] [Abstract][Full Text] [Related]
20. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y
Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
